Tesofensine

Tesofensine (NS2330) is a small-molecule triple monoamine reuptake inhibitor with the chemical name (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane. Its molecular formula is C17H23Cl2NO with a molecular weight of 328.28 Da. CAS number: 195875-84-4. It is a tropane derivative structurally related to phenyltropanes but with a distinct pharmacological profile that favors norepinephrine and serotonin reuptake inhibition over dopamine. Tesofensine is not a peptide but a synthetic small molecule, making it orally bioavailable without the need for injection.

Tesofensine inhibits the reuptake of three monoamine neurotransmitters by blocking their respective membrane transporters: the norepinephrine transporter (NET), serotonin transporter (SERT), and dopamine transporter (DAT). Its relative potency is NET > SERT > DAT, meaning norepinephrine effects predominate. NET inhibition increases sympathetic nervous system tone, activating brown adipose tissue thermogenesis and increasing resting energy expenditure. SERT inhibition enhances serotonergic tone in hypothalamic appetite circuits, particularly 5-HT2C receptor-expressing POMC neurons, producing satiety and reducing meal size. DAT inhibition modestly increases dopamine in mesolimbic circuits, reducing reward-driven eating and hedonic food consumption without producing the euphoria or abuse potential associated with strong DAT inhibitors like amphetamines. The net effect is a two-pronged attack on energy balance: reduced caloric intake via central appetite suppression plus increased caloric expenditure via sympathetically-mediated thermogenesis.

The pivotal Phase 2 trial (N=203), published in The Lancet in 2008 (DOI: 10.1016/S0140-6736(08)61525-1), randomized obese participants (BMI 30-40) to tesofensine 0.25mg, 0.5mg, or 1.0mg daily versus placebo over 24 weeks. Mean weight loss was 6.7% (0.25mg), 11.3% (0.5mg), and 12.8% (1.0mg) versus 2.2% placebo. At the 0.5mg dose, which showed the best benefit-risk ratio, 32.1% of participants lost more than 10% body weight. The TIPO-4 Phase 3 trial, conducted by Saniona, evaluated tesofensine 0.5mg in 372 participants and confirmed significant weight loss with an acceptable safety profile. Resting energy expenditure increased by approximately 6% at the 0.5mg dose, confirming the thermogenic contribution to weight loss beyond appetite suppression alone.

Tesofensine has a plasma half-life of approximately 8-9 days (200+ hours), which is exceptionally long for a small molecule. This extended half-life is due to high lipophilicity and extensive tissue distribution. Peak plasma concentration is reached 6-8 hours after oral administration. Steady state is achieved after approximately 6-8 weeks of daily dosing. Tesofensine is metabolized primarily by CYP3A4 to its active metabolite M1, which also inhibits monoamine reuptake but with lower potency. Both parent compound and M1 contribute to clinical effects. The long half-life means effects persist for days after discontinuation, which is relevant for washout in research settings. Elimination is primarily fecal.

Tesofensine is supplied as an oral capsule and should be stored at controlled room temperature (15-25C) in the original container, protected from moisture and light. No reconstitution is required. Capsules maintain stability for 24+ months when stored properly. For research settings requiring dissolution, tesofensine is soluble in DMSO and ethanol but has limited aqueous solubility.

Tesofensine is studied in research on central appetite regulation, monoamine neurotransmitter systems, brown adipose tissue activation, reward-driven eating behavior, and combination approaches with GLP-1 agonists. Its unique mechanism -- central monoamine modulation -- makes it complementary to peripheral incretin-based therapies. Researchers also study its effects on cognitive function, motor symptoms, and fatigue, reflecting its origins in neurodegenerative disease programs. Preclinical studies have explored its effects on binge eating models and food addiction paradigms.

In the Phase 2 trial, the most common adverse events were dry mouth (34.5% at 1mg vs 3.9% placebo), insomnia (24.1% vs 7.8%), constipation (17.2% vs 5.9%), and hard stools (13.8% vs 3.9%). Heart rate increased by a mean of 7.4 bpm at the 1mg dose and 1.6 bpm at the 0.5mg dose, compared to 0.6 bpm with placebo. Blood pressure changes were not clinically significant. No serious cardiovascular events were reported. The 0.5mg dose was selected for Phase 3 development based on its favorable balance of efficacy (11.3% weight loss) and tolerability (heart rate increase of only 1.6 bpm). No abuse potential signals were observed in clinical or preclinical studies.